{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Colodette NM"],"funding":["Conselho Nacional de Desenvolvimento Científico e Tecnológico","Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos","Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro","Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (BR)"],"pagination":["1091-1103"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7324290"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(10)"],"pubmed_abstract":["Herein, the LASSBio Chemical Library is presented as a valuable source of compounds for screening to identify hits suitable for subsequent hit-to-lead optimization stages. A feature of the LASSBio Chemical Library worth highlighting is the fact that it is a smart library designed by medicinal chemists with pharmacological activity as the main priority. The great majority of the compounds part of this library have shown in vivo activity in animal models, which is an indication that they possess overall favorable bioavailability properties and, hence, adequate pharmacokinetic profiles. This, in turn, is supported by the fact that approximately 85% of the compounds are compliant with Lipinski's rule of five and ca. 95% are compliant with Veber's rules, two important guidelines for oral bioava"],"journal":["Journal of computer-aided molecular design"],"pubmed_title":["Novel phosphatidylinositol 4-kinases III beta (PI4KIIIβ) inhibitors discovered by virtual screening using free energy models."],"pmcid":["PMC7324290"],"funding_grant_id":["001","309229/2018-9","465.249/2014-0","E-26/202.146/2015"],"pubmed_authors":["Barreiro EJ","Franco LS","Sant'Anna CMR","Colodette NM","Maia RC","Fokoue HH"],"additional_accession":[]},"is_claimable":false,"name":"Novel phosphatidylinositol 4-kinases III beta (PI4KIIIβ) inhibitors discovered by virtual screening using free energy models.","description":"Herein, the LASSBio Chemical Library is presented as a valuable source of compounds for screening to identify hits suitable for subsequent hit-to-lead optimization stages. A feature of the LASSBio Chemical Library worth highlighting is the fact that it is a smart library designed by medicinal chemists with pharmacological activity as the main priority. The great majority of the compounds part of this library have shown in vivo activity in animal models, which is an indication that they possess overall favorable bioavailability properties and, hence, adequate pharmacokinetic profiles. This, in turn, is supported by the fact that approximately 85% of the compounds are compliant with Lipinski's rule of five and ca. 95% are compliant with Veber's rules, two important guidelines for oral bioava","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2026-05-01T10:28:36.243Z","creation":"2020-07-05T07:10:36Z"},"accession":"S-EPMC7324290","cross_references":{"pubmed":["32601839"],"doi":["10.1007/s10822-020-00327-9"]}}